Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
Date:5/4/2012

MOUNTAIN VIEW, Calif., May 4, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2012.

The net loss for the first quarter ended March 31, 2012 was $17.8 million, compared to a net loss of $16.0 million during the same period in 2011. The net loss for the first quarter ended March 31, 2012 included a one-time expense of $2.8 million for the purchase of a data package relating to the propellant used for LEVADEX. MAP Pharmaceuticals had $79.0 million in cash and cash equivalents as of March 31, 2012, compared to $98.8 million as of December 31, 2011.

"Following receipt of the Complete Response letter from the FDA on March 26 for our LEVADEX NDA submission, we will meet with the FDA in the second quarter of this year and we look forward to gaining clarity around the issues raised in the letter," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "We believe that LEVADEX has the potential to be an important treatment for many of the 30 million Americans who suffer from migraine, and we will continue to closely collaborate with the FDA to address the issues raised in the Complete Response letter as quickly as possible."

Revenues for the first quarter ended March 31, 2012 were $1.0 million, compared to $0.6 million for the same period in 2011. The revenues for both periods were due to amortization of a $60.0 million nonrefundable upfront cash payment received in February 2011, pursuant to a collaboration agreement with Allergan, Inc. entered into in January 2011.

Research and development (R&D) expenses for the first quarter ended March 31, 2012 were $11.0 million, compared to $11.6 million for the same period in 2011. The decrease in R&D expenses for the three months ended March 31, 2012 was caused primarily by a decrease in expen
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
2. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
3. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
4. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
5. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
6. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
7. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
8. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
10. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
11. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. ... company focused on licensing, developing and commercializing innovative ... pricing of its public offering of 4,500,000 shares of its ... of $9.25 per share. Aratana has granted the ... an additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... Suwanee, GA (PRWEB) September 17, 2014 ... proud to announce the launch of its new vegan ... mask is extremely effective and provided the results skincare ... was to create a gentle yet active mask that ... CEO Lake Louise.” , This Sugar Cane Fruit Mask ...
(Date:9/17/2014)... -- Present-day Europeans are the descendants of at ... a new study. Previous research suggested ... European farmers. But, a new genetic analysis involving ... descendants of Ancient North Eurasians. Nearly all present-day ... group, researchers from Harvard Medical School said. , ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, ... who turn to artificial sweeteners to soothe their sweet ... new Israeli study suggests. Artificial sweeteners can potentially ... researchers found in human and mouse studies. That,s ... bacteria residing in the intestines in ways that can ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... in what triggers jealousy in men and women, study finds ... in the eye of the beholder, a new study suggests. ... to men while emotional infidelity may be of greater concern ... experiences in previous relationships may be even more important. , ...
... notes bloating, stomach pain, fatigue also point to less ... Relying on symptoms alone to identify women who have ... early, a new study indicates. , Research shows that ... healthy women to report symptoms such as abdominal pain, ...
... Jan. 28 Baylor Sammons Breast Center at ... has been recognized by the National Accreditation Program for Breast ... every significant advantage in their battle against breast disease." The ... NAPBC. Accreditation by the NAPBC is only given to those ...
... , ST. PAUL, Minn. , Jan. 28 ... -based Campbell Mithun, has been named Event Chair for this year’s ... Minnesota’s only nonprofit organization to supply life-saving blood and blood components ... to have Jeff Naughtin on board to head this ...
... , TORRANCE, Calif. , Jan. 28 ... is often a renewed focus on personal health and nutrition. ... year are prebiotics and immune health. This is welcome news ... addresses both categories. , SPINS, the leading provider of ...
... past or future, study finds , THURSDAY, Jan. 28 (HealthDay ... look toward the future, their body language reflects their sense ... the University of Aberdeen fitted subjects with motion sensors and ... past. The bodies of those who thought about the future ...
Cached Medicine News:Health News:Personal History Linked to Feelings of Betrayal 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 3Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 2Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 3Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 2Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 3Health News:Sun Chlorella USA Positioned for Strong 2010 2
5.5 pointed curved blade. Octagonal handle....
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Medicine Products: